Sex differences in left ventricular remodelling, myocardial fibrosis and mortality after aortic valve replacement.
Aged
Aged, 80 and over
Aortic Valve
/ diagnostic imaging
Aortic Valve Stenosis
/ diagnostic imaging
Echocardiography
Female
Fibrosis
Heart Valve Prosthesis Implantation
/ methods
Humans
Kaplan-Meier Estimate
Longitudinal Studies
Male
Middle Aged
Myocardium
/ pathology
Postoperative Period
Prognosis
Sex Characteristics
United Kingdom
/ epidemiology
Ventricular Remodeling
/ physiology
AVR
CMR
aortic stenosis
Journal
Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
28
02
2019
revised:
07
06
2019
accepted:
08
06
2019
pubmed:
31
8
2019
medline:
12
6
2020
entrez:
31
8
2019
Statut:
ppublish
Résumé
To investigate sex differences in left ventricular remodelling and outcome in patients undergoing surgical or transcatheter aortic valve replacement (SAVR/TAVR). In this multicentre, observational, outcome study with imaging core-lab analysis, patients with severe aortic stenosis (AS) listed for intervention at one of six UK centres were prospectively recruited and underwent cardiovascular magnetic resonance imaging. The primary endpoint was all-cause mortality and secondary endpoint was cardiovascular mortality. 674 patients (425 men, 249 women, age 75±14 years) were included: 399 SAVR, 275 TAVR. Women were older, had higher surgical risk scores and underwent TAVR more frequently (53% vs 33.6%, p<0.001). More men had bicuspid aortic valves (BAVs) (26.7% vs 14.9%, p<0.001) and demonstrated more advanced remodelling than women. During a median follow-up of 3.6 years, 145 (21.5%) patients died, with no significant sex difference in all-cause mortality (23.3% vs 20.5%, p=0.114), but higher cardiovascular mortality in women (13.7% vs 8.5%, p=0.012). There were no significant sex-related differences in outcome in the SAVR or TAVR subgroups, or after excluding those with BAV. Factors independently associated with all-cause mortality were age, left ventricular ejection fraction (LVEF), BAV (better) and myocardial fibrosis detected with late gadolinium enhancement (LGE) in men, and age, LVEF and LGE in women. Age and LGE were independently associated with cardiovascular mortality in both sexes. Men demonstrate more advanced remodelling in response to a similar severity of AS. The higher cardiovascular mortality observed in women following AVR is accounted for by women having less BAV and higher risk scores resulting in more TAVR. LGE is associated with a worse prognosis in both sexes.
Identifiants
pubmed: 31467152
pii: heartjnl-2019-314987
doi: 10.1136/heartjnl-2019-314987
pmc: PMC6900227
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1818-1824Subventions
Organisme : British Heart Foundation
ID : FS/10/015/28104
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/11/126/29321
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/17/34/32901
Pays : United Kingdom
Organisme : Department of Health
ID : PDF-2011-04-051
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/10/026/28209
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/08/028/24767
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/07/068/2334
Pays : United Kingdom
Organisme : Department of Health
ID : RP-2017-08-ST2-007
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/10/40/28260
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/78/31020
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/10/026
Pays : United Kingdom
Organisme : Department of Health
ID : DRF-2013-06-102
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/16/31/32185
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
JACC Cardiovasc Imaging. 2018 Jul;11(7):962-973
pubmed: 29153564
Circulation. 2009 Aug 18;120(7):577-84
pubmed: 19652094
Eur Heart J. 1995 Oct;16(10):1410-9
pubmed: 8746910
J Am Coll Cardiol. 2014 Jul 15;64(2):144-54
pubmed: 25011718
Eur Heart J. 2017 Apr 21;38(16):1222-1229
pubmed: 28204448
Circulation. 2018 Oct 30;138(18):1935-1947
pubmed: 30002099
Heart. 2013 Aug;99(16):1185-91
pubmed: 23749779
Eur Heart J. 2018 Feb 21;39(8):699-709
pubmed: 29020257
J Am Coll Cardiol. 2016 Dec 27;68(25):2733-2744
pubmed: 28007135
Eur Heart J. 2016 Feb 21;37(8):713-23
pubmed: 26491110
J Am Coll Cardiol. 2012 Feb 7;59(6):566-71
pubmed: 22300690
Am Heart J. 2016 May;175:101-11
pubmed: 27179729
Int J Surg. 2009 Jun;7(3):214-7
pubmed: 19332158
Circulation. 1992 Oct;86(4):1099-107
pubmed: 1394918
Anesth Analg. 2006 Oct;103(4):800-8
pubmed: 17000785
J Am Heart Assoc. 2017 Sep 21;6(9):null
pubmed: 28935681
J Am Coll Cardiol. 2017 Apr 4;69(13):1755-1756
pubmed: 28359524
Br Heart J. 1995 Jun;73(6):548-54
pubmed: 7626355
J Am Coll Cardiol. 2014 Apr 22;63(15):1522-8
pubmed: 24561149
J Card Surg. 2014 Nov;29(6):772-8
pubmed: 25264220
Am J Cardiol. 1994 Oct 15;74(8):794-8
pubmed: 7942552
JACC Cardiovasc Imaging. 2019 Jan;12(1):96-105
pubmed: 29248646
Eur Heart J Cardiovasc Imaging. 2018 Jan 1;19(1):3-8
pubmed: 29029001
J Thorac Cardiovasc Surg. 2003 Oct;126(4):959-64
pubmed: 14566232
J Am Coll Cardiol. 2011 Sep 13;58(12):1271-9
pubmed: 21903062
J Cardiovasc Magn Reson. 2017 Dec 7;19(1):98
pubmed: 29212513
Circulation. 1994 Nov;90(5 Pt 2):II183-9
pubmed: 7955249
J Heart Valve Dis. 2007 Jul;16(4):362-9
pubmed: 17702360